CompletedNCT00420823
A Study of Taurine in Patients With First-episode Psychosis Receiving Antipsychotic Treatment
Medication studyAges 18–25AustraliaSchizophrenia
Understand this study
Who was this study for?
Listed age limits: 18 years to 25 years.
- Listed locations
- Melbourne and 1 more locationSee all locations and recruitment
- Study phase
- Phase 2 / Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
Study information
Study start dateJanuary 2007
- Recruitment status
- Completed
- Enrollment listed in the registry
- 121
- Sponsor
- Melbourne Health
- Sponsor type
- Unknown or unclear
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 2, Phase 3This study spans more than one phase, so it may combine goals such as safety, dosing, and early effectiveness.
- Locations
- Australia
- Age range
- From 18 Years to 25 Years
- Official registry ID
- NCT00420823
- Official title
Show the full official title
A 12-week, Parallel, Double-blind, Randomised, Placebo-controlled Adjunctive Study of Taurine 4 Grams in 128 Patients With First-episode Psychosis Receiving Antipsychotic Treatment.
Get this study by email
Recruitment & locations
CompletedMelbourne
Questions about this study
Who is behind this study?
The study sponsor is Melbourne Health.
Did this study involve medication?
Yes. The study involved medication, including Taurine 4g.
Who was this study for?
Listed age limits: 18 years to 25 years.
Want to explore more studies?
Explore studiesRelated studies
A 26-Week Extension Study of EVP-6124 (Alpha-7 nAChR) as an Adjunctive Pro-Cognitive Treatment in Schizophrenia Subjects on Chronic Stable Atypical Antipsychotic Therapy
A Definitive Estrogen Patch Study (ADEPT)